Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir™ versus continued HAART: The trizal study

Alain Lafeuillade, Nathan Clumeck, Josep Mallolas, Hans Jaeger, Jean Michel Livrozet, Maria do Sameira Ferreira, Margaret Johnson, Arnaud Cheret, Zeina Antoun, J. Demonty, C. Bazin, M. Bentata, E. Bouvet, J. F. Delfraissy, P. Dellamonica, T. Saint Marc, L. De Saint Martin, P. De Truchis, G. Dien, H. GallaisH. Gil, B. Hoen, C. Katlama, D. Lacoste, J. M. Lang, J. M. Livrozet, M. Beumont, P. Massip, W. Rozenbaum, D. Sereni, P. Yeni, S. Fenske, J. Rockstroh, B. Salzberger, D. Schuermann, S. Staszewski, F. Mulcahy, A. Lazzarin, F. Milazzo, M. Moroni, A. Cargnel, C. Santos, L. Flamholc, K. Koppel, P. Easterbrook, M. Fisher, B. Gazzard, G. Kinghorn, J. Weber, E. Wilkins

Research output: Contribution to journalArticle

Abstract

Purpose: To analyze the evolution of clinical lipodystrophy (LD) and metabolic abnormalities in patients continuing to receive HAART versus patients switched to Trizivir™ (zidovudine, lamivudine, abacavir) after 48 weeks. Method: Patients treated with HAART >6 months with plasma HIV-1 RNA viral load (VL)

Original languageEnglish
Pages (from-to)37-43
Number of pages7
JournalHIV Clinical Trials
Volume4
Issue number1
DOIs
Publication statusPublished - Jan 2003

Keywords

  • Lipids
  • Lipodystrophy
  • Trizivir™

ASJC Scopus subject areas

  • Virology
  • Immunology

Fingerprint Dive into the research topics of 'Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir™ versus continued HAART: The trizal study'. Together they form a unique fingerprint.

  • Cite this

    Lafeuillade, A., Clumeck, N., Mallolas, J., Jaeger, H., Livrozet, J. M., do Sameira Ferreira, M., Johnson, M., Cheret, A., Antoun, Z., Demonty, J., Bazin, C., Bentata, M., Bouvet, E., Delfraissy, J. F., Dellamonica, P., Saint Marc, T., De Saint Martin, L., De Truchis, P., Dien, G., ... Wilkins, E. (2003). Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir™ versus continued HAART: The trizal study. HIV Clinical Trials, 4(1), 37-43. https://doi.org/10.1310/EJRF-JGGH-GRCD-MED8